Literature DB >> 2523688

New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance.

P B Fernandes1, W R Baker, L A Freiberg, D J Hardy, E J McDonald.   

Abstract

Macrolide-resistant bacteria can be classified as inducibly resistant or constitutively resistant. Inducibly resistant bacteria are resistant to 14-membered macrolides, such as erythromycin and clarithromycin (A-56268), but are susceptible to the 16-membered macrolides, such as tylosin and spiramycin, as well as to clindamycin. Constitutively resistant bacteria are resistant to macrolide-lincosamide-streptogramin B antibiotics. In this study, the MICs of several erythromycin and clarithromycin analogs against macrolide-susceptible and macrolide-resistant Streptococcus pyogenes strains were determined. Four 11,12-carbamate analogs of clarithromycin had lower MICs than erythromycin did against S. pyogenes with the inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Five 11,12-carbonate analogs of erythromycin with modifications at the 4" position of cladinose had lower MICs than did erythromycin against S. pyogenes with the constitutive type of resistance, and one of these compounds, which had a naphthyl-glycyl substitution at the 4" position, had a lower MIC than erythromycin against both the inducibly resistant and constitutively resistant strains. Two analogs of erythromycin with a modification on the 4" position of cladinose had lower MICs than erythromycin did against the constitutively resistant organisms but not against the inducibly resistant organisms. Thus, 14-membered macrolides can be modified so as to confer a low MIC when tested in vitro.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523688      PMCID: PMC171424          DOI: 10.1128/AAC.33.1.78

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Differential effect of hydroxyurea on the replication of plasmid and chromosomal DNA in Bacillus subtilis.

Authors:  A G Shivakumar; D Dubnau
Journal:  J Bacteriol       Date:  1978-12       Impact factor: 3.490

Review 2.  Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics.

Authors:  D Dubnau
Journal:  CRC Crit Rev Biochem       Date:  1984

Review 3.  Inducible erythromycin resistance in bacteria.

Authors:  B Weisblum
Journal:  Br Med Bull       Date:  1984-01       Impact factor: 4.291

4.  Inhibition of methyltransferases by some new analogs of S-adenosylhomocysteine.

Authors:  R W Fuller; R Nagarajan
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

5.  Molecular epidemiology of macrolides-lincosamides-streptogramin B resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  S Thakker-Varia; W D Jenssen; L Moon-McDermott; M P Weinstein; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

6.  Erythromycin-inducible resistance in Staphylococcus aureus: requirements for induction.

Authors:  B Weisblum; C Siddhikol; C J Lai; V Demohn
Journal:  J Bacteriol       Date:  1971-06       Impact factor: 3.490

7.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-03       Impact factor: 7.616

8.  Inducible and constitutive resistance to macrolide antibiotics and lincomycin in clinically isolated strains of Streptococcus pyogenes.

Authors:  S L Hyder; M M Streitfeld
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

9.  Sensitivity of group A streptococci to antibiotics. Prevalence of resistance to erythromycin in Japan.

Authors:  S Maruyama; H Yoshioka; K Fujita; M Takimoto; Y Satake
Journal:  Am J Dis Child       Date:  1979-11

10.  Macrolide resistance in Staphylococcus aureus: inducers of macrolide resistance.

Authors:  N E Allen
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

View more
  12 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  M M París; S Shelton; M Trujillo; S M Hickey; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Binding of novel macrolide structures to macrolides-lincosamides-streptogramin B-resistant ribosomes inhibits protein synthesis and bacterial growth.

Authors:  R C Goldman; S K Kadam
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

5.  A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.

Authors:  A Rosato; H Vicarini; A Bonnefoy; J F Chantot; R Leclercq
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 6.  The evolving role of chemical synthesis in antibacterial drug discovery.

Authors:  Peter M Wright; Ian B Seiple; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-02       Impact factor: 15.336

7.  In vitro activity of azithromycin against bacterial enteric pathogens.

Authors:  M E Gordillo; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 8.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 9.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 10.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.